Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 1, 2022Journal of Lipid and AtherosclerosisOpen Access

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The mechanisms underlying the salutary effects of SGLT2 inhibitors in heart failure have not been fully elucidated, and the specific contribution of ketone bodies requires further clarification.

Design

Review

Key result

SGLT2 inhibitors improve cardiac function in heart failure patients through pleiotropic effects, potentially including optimized energy metabolism via increased ketone body levels.

Authors

HSHuitzilihuitl Saucedo‐OrozcoSVSuzanne N. VoorripsSYSalva R. Yurista

Discussion

Loading...

Member takes

Overview

Does not support practice change in HF; leaves open the role of ketone metabolism in SGLT2 inhibitor benefits.

Structured PICO

P
Population
Patients with heart failure (both preserved and reduced ejection fraction, with or without type 2 diabetes)
I
Intervention
SGLT2 inhibitors

This review discusses the mechanisms underlying the cardiovascular benefits of SGLT2 inhibitors in heart failure, focusing on ketone metabolism, ventricular remodeling, and inflammation.

Limitations

  • The exact contribution of ketone bodies to the cardiovascular benefits of SGLT2 inhibitors requires further clarification.
  • Experimental and clinical evidence comparing the ketogenic effects of different SGLT2 inhibitors remains sparse.

Cite This Study

Saucedo‐Orozco et al. (2022) conducted a review in Heart failure. SGLT2 inhibitors was evaluated. SGLT2 inhibitors improve cardiac function in heart failure patients through pleiotropic effects, potentially including optimized energy metabolism via increased ketone body levels.

synapsesocial.com/papers/6a0eb0ac2eca052da647b206https://doi.org/10.12997/jla.2022.11.1.1
View Full Paper
Ask AI
Bookmark
Share